p27KIP1 is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome by Sáez, Al et al.
Cell cycle progression is promoted by the action of the cyclin-depen-
dent kinases (CDKs) and their activating sub-units, the cyclins. The
G1/S transition in mammalian cells is believed to be regulated by
complexes of Cyclin E/CDK2 and Cyclin D/CDK4 or CDK6; the
kinase activity of these CDKs requires an association between a
catalytic sub-unit, the CDK, and a regulatory sub-unit, the cyclin.
This kinase activity can be inhibited by various CDK inhibitors
(CDKis). There are two main groups of CDKis, the CIP1/KIP1
(p21WAF1/CIP1 (El-Deiry et al, 1993; Harper et al, 1993), p27KIP1 (Polyak
et al, 1994; Toyoshima and Hunter, 1994) and p57KIP2 (Lee et al,
1995; Matsuoka et al, 1995) and the INK4 (p16INK4A, p15INK4B,
p18INK4C and p19INK4D (Serrano et al, 1993; Guan et al, 1994; Hannon
and Beach, 1994; Chan et al, 1995)) families. Members of the
CIP1/KIP1 family share sequence homology, and are able to inhibit a
broader range of cyclin–CDKs. Nevertheless, members of the INK4
family mainly inhibit the kinase activity of CDK4-CDK6. All of
these CDKis cause G1 arrest when overexpressed in transfected cells.
p27KIP1 protein inhibits CDK activity by mediating cell cycle arrest
(Polyak et al, 1994; Toyoshima and Hunter, 1994). In vitro, p27KIP1
has been found to be involved in G1 arrest in response to extracellular
signals such as transforming growth factor (TGF)-bin epithelial cells
(Polyak et al, 1994), cell–cell contact in fibroblasts (Fang et al, 1995),
cAMP in murine macrophages (Kato et al, 1994) and rapamycin in T-
lymphocytes (Nourse et al, 1994), all of which are agents known to
inhibit cell cycle progression. p27KIP1 has been implicated as the
CDKi involved in mitogen-dependent CDK regulation, as a key
protein in passage through the restriction point (Couts et al, 1996),
thus making the p27KIP1 degradation a necessary step in the irre-
versible decision to enter the S phase (Cheng et al, 1998). p27KIP1
protein is present in quiescent cells, and levels descend dramatically
when cells are stimulated by growth factors (Kato et al, 1994; Nourse
et al, 1994). Besides this key role in cell cycle control, additional
functions for p27KIP1 in cell differentiation (Hengst and Reed, 1996),
apoptosis induction (Bani et al, 1995; Wang et al, 1997) and
chemotherapy resistance (Croix et al, 1996) have been proposed.
Knockout mice for p27KIP1 show an increase in the size of organs and
the cell number, confirming its inhibitory role in cell cycle control, in
the same regulatory pathway as the gene Retinoblastoma (Rb) (Fero
et al, 1996; Kiyokawa et al, 1996; Nakayama et al, 1996).
According to this model, quiescent non-tumoural lymphocytes
express high levels of p27KIP1 protein, which is down-regulated
following cell activation. Thus, proliferating lymphoid cells, in
either peripheral blood or peripheral lymphoid organs, express low
or undetectable levels of p27KIP1 protein (Croix et al, 1996;
Sánchez-Beato et al, 1997). In lymphomas, when all histological
types are taken into consideration, this relationship between p27KIP1
expression and proliferation is generally preserved, with an inverse
expression for p27KIP1 and MIB-1 proteins. Tumours with a low
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Summary Cell cycle progression is regulated by the combined action of cyclins, cyclin-dependent kinases (CDKs), and CDK-inhibitors
(CDKi), which are negative cell cycle regulators. p27KIP1 is a CDKi key in cell cycle regulation, whose degradation is required for G1/S
transition. In spite of the absence of p27KIP1 expression in proliferating lymphocytes, some aggressive B-cell lymphomas have been reported
to show an anomalous p27KIP1 staining. We analysed p27KIP1 expression in a series of Diffuse Large B-cell Lymphoma (DLBCL), correlating it
with the proliferative index and clinical outcome, to characterize the implications of this anomalous staining in lymphomagenesis in greater
depth. For the above mentioned purposes, an immunohistochemical technique in paraffin-embedded tissues was employed, using
commercially available antibodies, in a series of 133 patients with known clinical outcomes. Statistical analysis was performed in order to
ascertain which clinical and molecular variables may influence outcome, in terms of disease-free survival (DFS) and overall survival (OS). The
relationships between p27KIP1 and MIB-1 (Ki-67) were also tested. An abnormally high expression of p27KIP1 was found in lymphomas of this
type. The overall correlation between p27KIP1 and MIB-1 showed there to be no significant relationship between these two parameters, this
differing from observations in reactive lymphoid and other tissues. Analysis of the clinical relevance of these findings showed that a high level
of p27KIP1 expression in this type of tumour is an adverse prognostic marker, in both univariate and multivariate analysis. These results show
that there is abnormal p27KIP1 expression in DLBCL, with adverse clinical significance, suggesting that this anomalous p27KIP1 protein may be
rendered non-functional through interaction with other cell cycle regulator proteins.
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Correspondence to: MA Pirisproliferative index were mostly positive, while tumours character-
ized by a higher growth fraction had low p27KIP1 protein levels
(Sánchez-Beato et al, 1997), although in an earlier study performed
by this group some exceptions to this rule were found in the group
of aggressive B-cell lymphomas, including Burkitt’s lymphoma
and diffuse large B-cell lymphoma (DLBCL). Only very rare
genetic alterations have been found in the p27KIP1 gene (Shiohara
et al, 1994; Kawamata et al, 1995; Morosetti et al, 1995; Pietenpol
et al, 1995; Watanabe et al, 1995), suggesting that if inactivation
of this CDKi takes place in human tumours, it would be through
a mechanism other than genetic mutation, unlike the INK4 family.
Initial studies performed on breast, lung and colorectal cancer
and melanoma, coincide in indicating that a high level of p27KIP1
expression is associated in these tumours with a lower degree of
malignancy (Fredersdorff et al, 1997) or a better clinical outcome
(Bani et al, 1997; Catzavelos et al, 1997; Esposito et al, 1997;
Loda et al, 1997; Porter et al, 1997), in spite of the fact that in these
tumours there is no clear relationship between p27KIP1 expression
and growth fraction. Further studies offer differing data showing
that a high level of p27KIP1 expression may be associated with a
more aggressive course in breast cancer and B-cell lymphocytic
leukaemia (B-CLL) (Sgambato et al, 1997; Vrhorac et al, 1998).
The presence of an elevated level of p27KIP1 protein expression in
subsets of tumours with high proliferative indexes suggests that
the abnormally expressed protein lacks the functional capacity to
inhibit cell cycle progression (Fredersdorf et al, 1997; Sgambato et
al, 1997; Quintanilla-Martinez et al, 1998; Yatabe et al, 1998).
DLBCLs form a heterogeneous group in terms of clinical presen-
tation, histology, immunophenotype, genetic alterations, response to
treatment and prognosis (Harris et al, 1994). Recent findings suggest
that the overall outcome for patients with DLBCL is decided by a
combination of different clinical and biological variables, the
expression of some of these cell cycle regulator proteins being
specifically associated with different clinical features of tumours.
Overall analysis showed that an extended overall survival (OS) time
is associated with low growth fraction, low expression of p53 and
MDM2 proteins and high Rb expression. In contrast with this
finding, higher disease-free survival (DFS) time is mainly associated
with low bcl2 expression (Slymen et al, 1990; Yamanaka et al, 1992;
Miller et al, 1994; Piris et al, 1994; Martin et al, 1995; Hermine et al,
1996; Hill et al, 1996; Kramer et al, 1996; Gascoyne et al, 1997;
Grogan et al, 1988; Sánchez et al, 1998)
Earlier studies in non-Hodgkins lymphomas (NHLs) pointed to
the presence of a small group of DLBCL characterized by an
unusually high level of p27KIP1 expression (Sánchez-Beato et al,
1997; Quintanilla-Martinez et al, 1998), in which the opposing
relationship between p27KIP1 and MIB1 expression seemed to be
lost. The main purpose of this work was to analyse the expression
of this protein in greater depth, and to determine the clinical rele-
vance of p27KIP1 expression in this lymphoma type. To this end the
clinical characteristics of a series of 133 cases of DLBCL were
analysed, while simultaneously studying the relative clinical rele-
vance of MIB1 expression, which is a growth fraction marker.
MATERIALS AND METHODS
Tissue samples, patients and clinical variables
Tumour specimens from 133 DLBCLs were obtained from the
routine files of the Virgen de la Salud Hospital, and diagnosed
according to the criteria used in the REAL classification (Harris
et al, 1994). Consecutively diagnosed patients from 1980 to 1995
were included in the study if their cases fulfilled the following
conditions:
• The initial diagnosis of DLBCL had to be made on a represen-
tative biopsy obtained before treatment.
• Paraffin-embedded, formalin-fixed tissue blocks from the diag-
nostic biopsy had to be available for immunohistochemical
studies.
• All patients had to be treated with the aim of achieving a cure.
Untreated patients were excluded. Treatment decisions were
not based on molecular and/or immunohistochemical features.
Patients were treated according to standard therapeutic protocols,
including polychemotherapy (CHOP or third-generation regimes,
depending on IPI and clinical stage) and radiotherapy or surgery
for localized tumours. A combination of these treatments was used
for certain patients.
Age, clinical stage, performance status, LDH and the number of
extranodal sites of the disease were used, as determined by the
International Prognostic Index (IPI). IPI was grouped as 0–1, 2, 3
and 4–5. Complete remission (CR) was defined as the absence of
clinical and radiological evidence of disease for a minimum of 4
weeks. Other degrees of response were considered to represent
treatment failure. Patients who died of causes unrelated to the
disease were censored at the time of death. OS was measured as the
interval between the beginning of treatment and the death of the
patient or the date of the last follow-up revision. Patients known to
have died after finishing the treatment due to causes unrelated to the
lymphoma (one colorectal cancer diagnosed shortly after the diag-
nosis of lymphoma, one acute myocardial infarct and one elderly
patient with Alzheimer’s disease) were considered as censored for
the purposes of survival analysis. DFS was estimated for patients
having CR, by measuring the interval between the end of the treat-
ment and relapse or death attributable to the tumour, or the date of
the last follow-up revision in patients who had no relapse. All data
were checked for validity and consistency.
Antibodies
p27KIP1 protein was detected with a monoclonal antibody (mAb)
from Transduction Laboratories, K25020 (1:1000 dilution), gener-
ated against the full-length mouse KIP1 protein. This antibody
exclusively recognizes a 27 kDa protein, as previously shown by
Mantel et al (1996). Ki-67, a nuclear protein expressed in the G1,
S and G2/M phases, was detected by the MIB1 mAb (Novocastra)
(1:50 dilution). It was also used as the control of antigenic preser-
vation and successful antigenic retrieval.
Immunostaining techniques
All immunostaining techniques were performed in paraffin-
embedded tissue. A previous step of heat-induced antigen retrieval
technique was used for all four antibodies. This took the form of
pressure cooker heating in a solution of 0.01 M sodium citrate prior
to incubation with the antibody (Ab). Following incubation with
the primary Ab, immunodetection was performed with bio-
tinylated anti-mouse immunoglobulins, followed by peroxidase-
labelled streptavidine (LSAB-DAKO) and with diaminobencidine
chromogen as substrate. All immunostaining was performed using
the Techmate 500 (DAKO) automatic immunostaining device.
Incubation omitting the specific Ab, as well as with unrelated
Abs, was used as a control of the technique. Internal control
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endothelial cells was used to evaluate p27KIP1 and MIB1.
Quantitative studies
All scoring and interpretations of immunohistochemical results
were made by two pathologists (JFG and AIS), without knowledge
of the clinical outcome or other clinical variables of tumour
markers.
High magnification fields were chosen for the evaluation of
p27KIP1, focusing on tumoural areas, counting up to 200 cells,
excluding small T-cells or other non-tumoural cells. All
immunoreactive cells were considered positive. The percentage of
p27KIP1-positive tumoural cells was expressed as a ratio of positive
cells to 100 cells. A manual procedure of counting p27KIP1 cells
was used, in order to exclude all non-tumoural sub-populations
(most of them expressing p27KIP1), using the morphology of the
cells as criterion. A cut-off of 5% of tumoural cells was used for
p27KIP1 expression, since this threshold roughly separates tumours
with null or isolated p27KIP1 expression from those characterized
by an intermediate or high level of expression, as determined by
semi-quantitative analysis. This threshold divides the series into
groups of similar size (p27 ≤ 5%: 57.9% cases; p27 > 5%: 42.1%
cases), and this and closer cut-off points were found to be statisti-
cally highly significant. Moreover, the cut-off points at 4 and 6%
were statistically significant, although they had the disadvantage
of being less easily reproducible.
The Quantitative Proliferation Index application of the CAS 200
was used for the analysis of MIB1, since this measure of the
tumoural growth fraction has been shown to correlate significantly
with the clinical outcome in DLBCL (Sanchez-Bezto et al, 1997).
This program determines a value expressing the growth fraction of
the tumour, related to the number of proliferating cells.
Representative fields down to a minimum of 30 000 m2 were
selected (approximately five fields with 45´ objective and 10´
ocular lenses). Sectional analysis was carried out, focusing on
tumoural areas. A cut-off point of 20% of positive cells was used,
as a previous study showed that this point discriminated between
groups presenting different clinical behaviour. Categories were
therefore classified as equal to or less than 20%, or greater than
20% (Sánchez et al, 1998).
Statistical study
The relationship between p27 KIP1 and the proliferative index
The distributions of p27KIP1 and MIB-1 were compared in order to
establish any possible associations, using the Spearman correlation
coefficient for doubly ordered data, and Kruskal–Wallis test for
single ordered data. Differences were considered significant if
P < 0.05.
Survival: univariate analysis
The clinical variables analysed for survival studies were those
included in the IPI (measured as 0–1, 2, 3, 4–5), which are: age
(≤ 60 vs > 60), gender (female vs male), clinical stage (I + II vs III
+ IV), LDH (normal vs > normal). Actuarial survival curves (OS
and DFS) were plotted using the Kaplan and Meier method
(Kaplan and Meier, 1958). The statistical significance of associa-
tions between individual variables, OS and DFS was determined
by using the log-rank test (Mantel, 1966). Cox’s proportional
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Figure 1 Immunohistochemical expression of p27KIP1 and MIB1 in two
different cases of the series. Case 65 was characterized by low p27KIP1
expression (1%), mainly restricted to small lymphocytes and endothelial cells
(A), while most tumoural cells show strong MIB1 staining (B), read by the
image analyser as 44.16%. Case 112 shows distinct p27KIP1 staining of a
majority of tumoural cells (90%) (C) and relatively similar MIB1 staining (D)
(43.94%)hazard univariate analysis was also performed independently for
each variable, calculating the relative risk (RR) of each variable in
terms of survival and confidence interval (CI) (Cox, 1972).
Survival: multivariate analysis
In order to identify the factors which might be of independent
significance in influencing survival (OS and DFS), a Cox back-
ward proportional hazard model was run (Cox, 1972). Variables
included in the maximum models were: IPI (0–1, 2, 3 or 4–5),
MIB1 (≤ 20% or > 20%), p27KIP1 (≤ 5% or > 5%). The lower
values of IPI, MIB1 and p27KIP1, which had been found to be asso-
ciated with longer survival probability, were used as reference
levels (RL). All P-values were two-sided, and values of 0.05 or
less were considered to indicate statistical significance.
The SPSS software package was used for all statistical analysis.
RESULTS
Characteristics of the patients
The clinical characteristics of the 133 patients included in this
analysis have already been published (Sánchez et al, 1998).
Immunohistochemical study
p27KIP1 nuclear protein expression was observed in tumoural cells
with a signal range of from 0.00 to 95.00 and with a median of
3.00. Null p27KIP1 staining was seen in 21 cases. p27KIP1 staining
was found most frequently in a low to intermediate proportion of
the tumoural cells. For survival analysis, a cut-off point of 5% of
p27KIP1-positive cells was used, which divides the series into
two groups, corresponding approximately to cases found by semi-
quantitative analysis as negative or low-expression versus those
with intermediate or high levels of expression (p27 ≤ 5%: 77 cases;
p27 > 5%: 56 cases). A smaller group of seven cases (corre-
sponding to percentile 95) showed a very high intensity of staining
of most tumoural cells (Figure 1). A histogram of the overall
distribution of p27KIP1 reactivity is shown in Figure 2.
MIB1 expression was observed in all cases, with a positive
percentage of cell staining varying from 2.912 to 55.94 (median:
22.030) (Figure 1). In 73 cases (54.9%) the growth fraction was
greater than 20%, this threshold having been found to be clinically
relevant in previous studies (Sánchez et al, 1998). No significant
correlation was found between p27KIP1 and MIB-1 expression,
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Figure 2 Histogram of p27KIP1 expression in the DLBCL series
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Figure 3 Analysis of lineal correlation between p27KIP1 and MIB1. There is not a significant correlation between these two parametersusing the Spearman correlation coefficient (r = 0.0617, P = 0.482)
or the Kruskal–Wallis test (c2 = 0.0741, P = 0.7854) (Figure 3).
Survival analysis
Univariate and multivariate survival analyses were performed to
analyse the prognostic significance of p27KIP1 expression. MIB1
expression and the clinical parameters included in the IPI were
included as references.
Univariate study
Investigation of OS by Cox’s analysis showed that high IPI (P =
0.0004), MIB1 > 20% (P = 0.0199) and p27KIP1 > 5% (P = 0.0320)
were significantly associated with shorter OS. The study of DFS
showed that a high expression of p27KIP1 (P = 0.0412) is signifi-
cantly associated with shorter DFS. No significant relationship
was found for high MIB1 or IPI (Table 1). Figure 4A shows the
plots for OS, while Figure 4B shows the plot for DFS by
Kaplan–Meier analysis and log-rank test.
Multivariate study
Only low p27KIP1 expression was found to be a parameter associ-
ated with prolonged OS (P = 0.0145), together with the clinical
variables included within the IPI (P = 0.0010). The significance of
MIB1, as found in univariate analysis, was absent from this series.
When analysing DFS, only a high p27KIP1 value was found to be
significantly associated with a shorter DFS time (P = 0.0424)
(Table 1).
DISCUSSION
This study confirms that there is a group of DLBCL characterized
by an anomalous p27KIP1 expression, showing that in the DLBCL
group as a whole the inverse relationship found in normal lymphoid
p27 KIP1 in diffuse large B-cell lymphomas 1431
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Table 1 Univariate and multivariate analysis of the prognostic significance of p27KIP1 and MIB1 expression in relation with the clinical parameters included
within the IPI (Cox’s regression model)
Univariate study Multivariate study
RL RR 95% CI P RR 95% CI P
P27 ≤5% 1.6491 1.0438–2.6053 0.0320 1.7811 1.1210–2.8300 0.0145
MIB1 ≤20% 1.7554 1.0931–2.8190 0.0199 1.5514 0.9420–2.5550 0.0845
IPI 0.0004 0.0010
IPI(2) IPI(0–1) 2.7338 1.2761–5.8568 0.0097 2.7513 1.2796–5.9156 0.0096
IPI(3) IPI(0–1) 3.5224 1.6555–7.4945 0.0011 3.6285 1.7024–7.7337 0.0008
IPI(4–5) IPI(0–1) 4.8971 2.3176–10.3474 0.0000 4.5606 2.1337–9.7479 0.0001
Disease-free survival
P27 ≤5% 2.2732 1.0334–5.0005 0.0409 2.2899 1.0349–5.0669 0.0409
MIB1 ≤20% 1.1531 0.5180–2.5668 0.7271 1.4448 0.6060–3.4446 0.4065
IPI 0.1475 0.1148
IPI(2) IPI(0–1) 2.6184 0.9204–7.4491 0.0712 2.6280 0.9133–7.5620 0.0732
IPI(3) IPI(0–1) 3.1793 1.1018–9.1740 0.0324 3.3917 1.1662–9.8646 0.0250
IPI(4–5) IPI(0–1) 1.4543 0.2931–7.2165 0.6468 1.1496 0.2169–6.0924 0.8698
Chi-square: 28.949, P < 0.0001 for overall survival; Chi-square: 10.736, P = 0.0569 for disease-free survival. RL: reference level; RR: risk ratio; CI: confidence
interval.
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Figure 4 Overall survival (A) and disease-free survival (B). Kaplan–Meier analysis of the series according to p27KIP1 expression. Both OS and DFS were found
to be significantly shortened in cases of DLBCL with higher p27KIP1 expressiontissues between p27KIP1 and MIB1 expression is lacking. This
anomalous p27KIP1 expression was also associated with an adverse
clinical outcome in univariate as well as multivariate analysis.
This finding contradicts observations in reactive lymphoid
tissue, where p27KIP1 expression is always associated with quies-
cent status, as shown by immunohistochemistry of reactive
lymph nodes and tonsils, flow cytometry and Western blot
studies of phytohaemaglutinin-stimulated peripheral blood
lymphocytes. These show that the p27KIP1 protein is mainly found
in MIB-1 negative quiescent lymphocytes, its expression being
down-regulated along cell cycle progression (Sánchez-Beato et
al, 1997). Thus benign centroblasts, the proliferating B-cell
subset of the germinal centre and the supposed normal counter-
part of most DLBCL, usually show a MIB1+, p27– phenotype,
which is lost to a certain extent in DLBCL. This had already been
noticed in a previous study of NHL by our group, in which the
existence of a small group of cases of Burkitt’s lymphoma and
DLBCL with this anomalous nuclear p27KIP1 accumulation was
described (Sánchez-Beato et al, 1997); these results were
confirmed by further studies by Quintanilla-Martínez et al (1998)
and Erlanson et al (1998). A more detailed study was therefore
performed. This analysed a larger series of cases using a more
sensitive technique and quantified the results with a more analyt-
ical procedure, including statistical analysis of the relationship
between p27KIP1, MIB1 and survival probability. This made it
possible to confirm and expand earlier observations, indicating
that a gradient of p27KIP1 expression may be seen in DLBCL.
Contrary to what was expected on the basis of the findings in
non-tumoural tissues and other tumours, p27KIP1 expression
appears to be associated with an unfavourable clinical course,
thereby supporting the hypothesis that this abnormal accumula-
tion of p27KIP1 protein is deregulated (Sgambato et al, 1997). To
exclude the possibility that the adverse effect of p27KIP1 expres-
sion on survival could be attributed exclusively to the small
group of cases with very high p27KIP1 expression, we repeated the
analysis excluding the cases with values of p27 > 25%, the same
findings being repeated in this group (data not shown). This same
series of patients was the subject of a recent report showing that
high growth fraction is an adverse prognostic factor in multi-
variate analysis (Sánchez et al, 1997). Now, and once p27KIP1 is
included in the analysis, the predictive value of MIB1 is lost in
favour of that of p27KIP1.
The techniques used here for the quantitative analysis of p27KIP1
and MIB1 reflect the difficulties arising in estimating these in
DLBCL. As is the case for most reactive T-cells, endothelial cells
and histiocytes are p27KIP1-positive. We therefore decided to count
the cells manually, thereby selecting tumoural cells exclusively on
the basis of their morphology. This made it possible to recognize
and estimate the presence of a minority p27-positive tumoural cell
subpopulation in a significant group of DLBCL. This finding was
also described in the other analysis published to date of p27KIP1
expression in DLBCL, thereby underlining the consistency of these
techniques and the reproducibility of the results described. Thus,
the studies of Quintanilla-Martínez et al (1998) and Erlanson et al
(1998) both describe the presence of anomalous p27KIP1 expression
in a subset of DLBCL cases, together with an associated loss of the
normal p27/MIB1 ratio found in normal cells.
Nevertheless, software specifically designed for the recognition
of the growth fraction of tumours was used for MIB1 analysis,
since most positive cells in DLBCL are members of the tumoural
cell population, which makes it possible to use an image analysis
program. A relatively low percentage of proliferating cells was
found in this study, depending of the characteristics of the software
used, and this must be taken into consideration when comparing
these values with those corresponding to other series.
Although the loss of the inverse relationship between p27KIP1
and MIB-1 expression has been described previously in different
studies of breast and colorectal cancer specimens and derived cell
lines (Catzavelos et al, 1997; Fredersdorf et al, 1997; Lodu et al,
1997; Sgambato et al, 1997), the existence of an adverse clinical
significance for increased expression of p27KIP1 in a specific
tumoural type has only been rarely noticed. Indeed, earlier reports
emphasized that a more favourable clinical outcome is usually
associated with a high level of p27KIP1 expression, as seen in non-
small-cell lung cancer (Esposito et al, 1997), breast cancer
(Catzavelos et al, 1997; Porter et al, 1997), colorectal cancer (Loda
et al, 1997). A recent report by Erlanson et al (1998) found that,
when all histological types of NHL are taken into consideration,
high p27KIP1 values are associated with longer survival probabili-
ties, and therefore probably reflect the fact that the study simulta-
neously includes different entities, while it does not analyse the
specific meaning of p27KIP1 expression in each histological type.
Nevertheless, when considering a specific entity like B-CLL, a
recent analysis by Vrhovac et al (1998) illustrates the same
phenomenon found here, i.e. high p27KIP1 levels associated with a
poorer overall prognosis, which appeared to be related to the asso-
ciation between high p27KIP1 and apoptosis resistance. These
results overlap those of other reports in epithelial tumours, in
which an anomalous deregulated p27KIP1 expression in some
tumoural cell types has been described (Sgambato et al, 1997;
Yatube et al, 1998).
It has been proposed that p27KIP1 overexpression is involved in
the drug resistance displayed by solid tumours, and the suggestion
has even been made that tumour-targeted p27KIP1 antagonists could
be used in conjunction with conventional anticancer therapy
(Croix et al, 1996). In B-CLL it has been shown that an increased
p27KIP1 level protects cells against apoptosis, this being reverted
after fludarabin exposure (Vrhorac et al, 1998). These experi-
mental data could explain the shorter survival in the patients
analysed here.
This abnormally accumulated p27KIP1 protein seems to lack the
capacity for inhibiting Cyclin E–CDK2 complexes, since these
aggressive B-cell lymphomas have a high proliferative index and
an unfavourable clinical outcome. This situation has also been
observed in human breast cancer cell lines, where an increase in
p27KIP1 expression was paralleled by an increase in the level of
Cyclin D1 and Cyclin E. As p27KIP1 expression is mainly regulated
at a post-transcriptional level, it has therefore been suggested that
there is a homeostatic mechanism for the up-regulation of p27KIP1,
induced by overexpression of Cyclin D1 or Cyclin E (Sgambato et
al, 1997). Additional works by Blain et al (1997), Cheng et al
(1998), Reynisdottir and Massague (1997) and Soos et al (1996)
have shown that a high level of p27KIP1 expression may be found in
growing cells, confirming that this negative regulator of the cell
cycle is kept inactive by adhesion to Cyclin D–CDK4 complexes.
This could also be an hypothetical explanation for the anomalous
p27KIP1 expression in this group of DLBCL.
It is still not known if the adverse clinical meaning of p27KIP1
expression in DLBCL is the direct consequence of the accumula-
tion of this protein, or whether it is merely a reflection of a deeper
alteration of cell cycle regulator genes leading to this anomalous
p27KIP1 expression.
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